AstraZeneca (AZN) Receives “top pick” Rating from Barclays
Several other analysts have also recently weighed in on AZN. Citigroup reaffirmed a buy rating on shares of AstraZeneca in a research note on Thursday, June 28th. UBS Group reaffirmed a neutral rating and set a GBX 5,600 ($71.58) price objective on shares of AstraZeneca in a research note on Monday, July 2nd. Credit Suisse Group set a GBX 5,900 ($75.42) price objective on shares of AstraZeneca and gave the stock a buy rating in a research note on Friday, July 27th. JPMorgan Chase & Co. reaffirmed an overweight rating and set a GBX 6,500 ($83.09) price objective on shares of AstraZeneca in a research note on Tuesday, August 7th. Finally, Shore Capital reaffirmed a hold rating on shares of AstraZeneca in a research note on Wednesday, June 27th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of GBX 5,605.09 ($71.65).
Shares of AstraZeneca stock opened at GBX 5,989.74 ($76.57) on Monday. AstraZeneca has a 1-year low of GBX 4,260 ($54.45) and a 1-year high of GBX 5,520 ($70.56).
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: Earnings Per Share
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.